Predicting Treatment Response Based on RNA Expression in Large Datasets.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30446588.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2823.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.<i>See related article by Ayers et al., p. 1564</i>.
Medical subject headings
- B7-H1 Antigen
- Neoplasms